Tolerance to malignant cells is a hallmark of cancer, and thus drugs that target arginases and IDO have been produced and tested in the context of immune enhancement of anti-tumor immunity (Steggerda et al., 2017; Günther et al., 2019). Here, IDO1 is linked to neoplasm.